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dictors of thrombolysis failure (p=0.006, OR=0.13 for class III, p=0.003,
OR=0.15 for class IV).
Conclusion: In our MIRAMI Registry, short time to treatment (< 3 hours),
smoking and inferior location of STEMI were predictors of thrombolysis suc-
cess , whereas severe heart failure was a predictor of its failure.
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Background: Very late stent thrombosis (VLST) of Drug Eluting Stents
(DES) is a rare but severe complication whose physiopathology and manage-
ment remain unclear. 
Aim: We carried out a prospective systematic analysis DES mechanical
structure with intravascular ultrasound (IVUS) for all patients who presented
with VLST. After this analysis, we proposed a VLST management therapy. 
Methods: Between June 2009 and August 2010, we included consecu-
tively all cases of VLST (definite ST with any Academic Research Consor-
tium definition) in our university hospital. All patients underwent IVUS
imaging. A VLST management therapy was proposed with balloon angio-
plasty if malapposition or underexpansion were detected. One year follow up
was performed. 
Results: Ten cases (9 men, 1 woman; mean age 61 years [39-81]) were
identified. The index procedure indication was acute coronary syndrome in 8
patients and stable pectoris angina in 2 patients. The mean duration from
implantation to thrombosis was 52 ± 15 months (range 19 to 66 months). All
patients except one had a correct anti-agreggation therapy at the moment of
VLST. All patients analysed with IVUS imaging had evidence of stent under-
expansion and/or malapposition. During interventions IVUS findings led to
the use of higher pressures or larger balloons than those used during initial
stenting. After the procedure the final minimum stent area (10.5 vs. 7.9 mm²,
p=0.03) and % stent expansion improved compared with pre-interventional
values (86 vs. 66%, p=0.03). At the follow-up (15±4.5 months), all patients
are alive without new MACEs (cardiac death, non fatal infarction and ST). 
Conclusion: In VLST management, the selective use of IVUS after an ini-
tial mechanical reperfusion is an attractive option to optimise mechanical stent
features and appeared effective and safe at 1 year follow-up.
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Background: Limited long-term outcome data is available to support the
use of drug-eluting stents in the treatment of unprotected left main (LM) cor-
onary artery disease.
Methods and Results: In this multicenter registry, 291 patients with
unprotected LM stenosis underwent percutaneous revascularization with pacl-
itaxel-eluting stents (Taxus Express), using a consistent technical approach for
both ostial/shaft and bifurcation lesions (provisional side-branch stenting). At
5 years, the cumulative incidence of major adverse cardiac events (MACE)
was 23.6%, and the crude rates of all-cause and cardiac death were 24.3% and
12.5% respectively. During follow-up, myocardial infarction occurred in
16 patients (6.1%) and the incidence of target lesion revascularization (TLR)
was 10.3%. Definite stent thrombosis occurred in 0.4%. There was no signif-
icant difference in outcomes between patients with ostial/shaft or bifurcation
lesions. In contrast, patients with distal LM lesions requiring two-stent proce-
dures had a higher rate of MACE than patients with single-stent interventions
(34.1% versus 17.8%, P=0.009). This was driven by an increased incidence of
cardiac death (18.2% versus 8.5%, P=0.05) and non-Q-wave MI (8.0% versus
1.7%, P=0.04) in the two-stent cohort. Patients with diabetes mellitus had an
increased rate of TLR compared to nondiabetic subjects (19.2% versus 6.8%,
P=0.005), and diabetes was an independent predictor of MACE at 5 years (OR
2.10, 95% CI 1.10-3.99, P=0.018).
Conclusions: These long-term results show that the treatment of unprotected
LM stenosis with paclitaxel-eluting stents is safe and efficacious. Outcomes
are similar for ostial/shaft and distal LM interventions, however single-stent
interventions should be the preferred strategy for distal LM lesions, as two-
stent techniques increase the risk of adverse events.
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Aim: To compare drug-eluting stent (DES) vs bare metal stent (BMS) in
diabetic patients treated by percutaneous coronary intervention (PCI) for short
lesions in large vessels (vessel diameter 3.0 mm AND length 15 mm). 
Methods: Consecutive patients treated with at least one large (3.0 mm)
and short (18 mm) stent were included over 29 months. Patients with MI,
cardiogenic shock or out-of-hospital cardiac arrest were excluded. We com-
pare the occurrence of 1) MACCE (cardiovascular (CV) death, myocardial
infarction and stroke), 2) Target Vessel (TVR) and – Lesion Revascularization
(TLR) and 3) definite Stent Thrombosis (ST) rates in the diabetic population
according to the type of stent used (DES vs BMS). 
Results: Six hundred eighty-six patients underwent PCI in large and short
lesions. Among the 189 (28%) patients with diabetes, 47% (n=89) had PCI
with BMS and 53% (n=100) with DES. Mean age was 66 ± 11 years, 34%
(n=64) had acute coronary syndrome. Patients treated with DES were younger
(64 vs. 69, p=0.001), had more prior PCI (41% vs. 22%, p=0.006) and more
multivessel disease (63% vs. 45%, p=0.013). Total stent length was higher in
the DES group (28±22 mm vs. 22±16 mm, p=0.043). One year follow-up was
completed for 100% of the patients. Twenty patients (10.5%) had MACCE, 17
(9.0%) TVR, 12 (6.3%) TLR and 3 (1.6%) ST. Figure shows event rates
according to the stent used. 
Conclusions: In diabetic patients treated by elective or emergent PCI of
short lesions in large vessels, comparable rates of TLR, TVR and Stent throm-
bosis were observed between DES and BMS. However, the DES group had a
higher risk profile of restenosis.
One year event rates
